What mattersShow
- The Toronto-based fund is targeting a total of $125 million USD
- Operational lens: Women's and children's health technology investments
- Open the company page to keep the follow-up signal in view.
Cross-Border Impact Ventures (CBIV) has secured the first tranche of funding for its second investment vehicle, raising $58 million USD ($81 million CAD) to focus on improving health outcomes for women and children. The Toronto firm aims to raise a total of $125 million USD by the second half of 2027 through this new fund dedicated to Women’s and Children’s Health Technology.
The capital will be deployed into roughly a dozen companies across biotech, medical devices, and diagnostics, generally writing Series A and Series B cheques between $2 million and $5 million USD. CBIV maintains a global lens for its investments, requiring target companies to demonstrate both strong commercial potential and a clear line of sight toward regulatory approval.
For Canadian medtech startups to attract international growth capital, they must proactively demonstrate a robust commercialization path and address the perceived scarcity of deal flow at the early growth stage.
The announcement highlights a significant operational tension: despite being based in Toronto, the fund has not yet invested in a Canadian company. The partners noted that finding deals at the early growth stages remains difficult due to what they described as a sparse medtech landscape for women’s health diagnostics and devices in Canada.
This local challenge occurs against a backdrop of declining funding activity; a recent report indicated life sciences saw a 39-percent year-over-year drop in funding activity in the Canadian venture capital sector. However, CBIV's continued fundraising efforts signal persistent international investor interest in impact-driven healthtech ventures, particularly those focused on gender and youth health.
The fund’s successful track record includes backing Sonio, a fetal ultrasound software company that was acquired by Samsung Medison for an estimated $92 million USD. The influx of capital from major limited partners like the German national development bank KfW underscores global confidence in dedicated impact funds, even as local Canadian early-stage medtech funding struggles to keep pace.
Get the week’s essential Canadian tech.
Five minutes. One useful email. No noise.
Sources & technical notesShowHide
Where this story is grounded
Use the public signals, research inputs, and editorial framing here to understand how the story was built.
What to evaluate next
This box highlights the systems, workflows, and decisions the article helps you assess.
Stay in the signal after this story.
Follow the company page, then jump into the broader sector hub before you leave the story.
Keep the company context attached as you read the rest of the coverage.
Weekly Canadian tech signals, distilled for operators.
Subscribe to the signalFree weekly briefing • Unsubscribe anytime
A practical checklist for Canadian policy, privacy, procurement, and governance teams who need a quick way to sanity-check AI deployments before they scale.
Request access